Proteomics Blood-Based Biomarker Discovery for ALS
Abstract
The objective to be reached upon completion of this proposal is the identification of blood-based biomarkers correlated with ALS progression and rate of progression. We will relate symptomatic clinical outcome measures from participants in our Precision Medicine Program to potential blood-based biomarkers by analyzing blood samples collected quarterly from the same participants. Clinical outcome measures used will include: 1) monthly self-assessed ALS-FRS-R measures, 2) accelerometer-based assessments of participants abilities to move their arms and legs, and 3) Machine Learning (ML)assisted, quantified assessment of speech dysarthria. Plasma samples will be analyzed using the SomaLogic trademark SomaScan trademark proteomics platform. Data analysis will include Machine Learning algorithms and Harvard University expert Dr. Michael Brenner. So far, 18 people have been enrolled and 5 blood samples have been collected. Enrollees have provided data on the clinical outcome measures described above.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2022
- Accession Number
- AD1190418
Entities
People
- Fernando Vieira
Organizations
- ALS Therapy Development Institute